相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2014)
Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2014)
One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2
W. J. Sandborn et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol
Xavier Hebuterne et al.
GUT (2013)
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn's Disease
Satish Keshav et al.
PLOS ONE (2013)
Is Certolizumab Pegol Safe and Effective in the Treatment of Patients with Moderate to Severe Crohn's Disease? A Meta-analysis of Controlled Clinical Trials
Shekoufeh Nikfar et al.
IRANIAN RED CRESCENT MEDICAL JOURNAL (2013)
Phosphodiesterase inhibitors in inflammatory bowel disease
Pooneh Salari et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Abatacept for Crohn's Disease and Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2012)
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2012)
Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose-ranging study
Asit Parikh et al.
INFLAMMATORY BOWEL DISEASES (2012)
A Comprehensive Review of Antibiotics in Clinical Trials for Inflammatory Bowel Disease
A. H. Abdolghaffari et al.
INTERNATIONAL JOURNAL OF PHARMACOLOGY (2012)
Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study
S. Schreiber et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab
B. G. Feagan et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol
B. G. Feagan et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Glucocorticosteroid Therapy in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
A systematic review and meta-analysis of the effects of infliximab on the rate of colectomy and post-operative complications in patients with inflammatory bowel disease
Solmaz Ehteshami-Afshar et al.
ARCHIVES OF MEDICAL SCIENCE (2011)
Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial
William J. Sandborn et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2011)
Melatonin, a Promising Supplement in Inflammatory Bowel Disease: A Comprehensive Review of Evidences
Shilan Mozaffari et al.
CURRENT PHARMACEUTICAL DESIGN (2011)
The correlation between NF-κB inhibition and disease activity by coadministration of silibinin and ursodeoxycholic acid in experimental colitis
Hadi Esmaily et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2011)
Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis
Keith Leiper et al.
GUT (2011)
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
Walter Reinisch et al.
GUT (2011)
Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease
S. B. Hanauer et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study
B. G. Feagan et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data
Stefan Schreiber et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis
Ali Rezaie et al.
ARCHIVES OF MEDICAL SCIENCE (2010)
Reinduction With Certolizumab Pegol in Patients With Relapsed Crohn's Disease: Results From the PRECiSE 4 Study
William J. Sandborn et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2010)
Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab
William J. Sandborn et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2010)
Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months
Gary R. Lichtenstein et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2010)
Efficacy and Tolerability of Immunoregulators and Antibiotics in Fistulizing Crohn's Disease: A Systematic Review and Meta-analysis of Placebo-controlled Trials
Shekoufeh Nikfar et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
World Gastroenterology Organization Practice Guidelines for the Diagnosis and Management of IBD in 2010
Charles N. Bernstein et al.
INFLAMMATORY BOWEL DISEASES (2010)
A review of the efficacy of traditional Iranian medicine for inflammatory bowel disease
Roja Rahimi et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2010)
Clinically Meaningful Improvement in Health-Related Quality of Life in a Randomized Controlled Trial of Certolizumab Pegol Maintenance Therapy for Crohn's Disease
Brian G. Feagan et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe - a Hungarian nationwide observational study
Pal Miheller et al.
BMC GASTROENTEROLOGY (2009)
Comparison of Mesalazine and Balsalazide in Induction and Maintenance of Remission in Patients with Ulcerative Colitis: A Meta-Analysis
Roja Rahimi et al.
DIGESTIVE DISEASES AND SCIENCES (2009)
A Meta-Analysis of the Efficacy of Sulfasalazine in Comparison with 5-Aminosalicylates in the Induction of Improvement and Maintenance of Remission in Patients with Ulcerative Colitis
Shekoufeh Nikfar et al.
DIGESTIVE DISEASES AND SCIENCES (2009)
On the Use of Herbal Medicines in Management of Inflammatory Bowel Diseases: A Systematic Review of Animal and Human Studies
Roja Rahimi et al.
DIGESTIVE DISEASES AND SCIENCES (2009)
Current Opinion in the Pharmaceutical Management of Irritable and Inflammatory Bowel Diseases: Role of ATP
Pooneh Salari et al.
RECENT PATENTS ON ENDOCRINE METABOLIC & IMMUNE DRUG DISCOVERY (2009)
Effects of Adalimumab Maintenance Therapy on Health-Related Quality of Life of Patients With Crohn's Disease: Patient-Reported Outcomes of the CHARM Trial
Edward V. Loftus et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin
Brian G. Feagan et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2008)
A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease
William J. Sandborn et al.
GASTROENTEROLOGY (2008)
Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFα, improves health-related quality of life in patients with moderate to severe Crohn's disease
Paul Rutgeerts et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2008)
Health-related quality of life during natalizumab maintenance therapy for Crohn's disease
Brian G. Feagan et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2007)
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
W. J. Sandborn et al.
GUT (2007)
Unravelling the pathogenesis of inflammatory bowel disease
R. J. Xavier et al.
NATURE (2007)
Certolizumab pegol for the treatment of Crohn's disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Maintenance therapy with certolizumab pegol for Crohn's disease
Stefan Schreiber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Adalimumab induction therapy for Crohn disease previously treated with infliximab - A randomized trial
William J. Sandborn et al.
ANNALS OF INTERNAL MEDICINE (2007)
Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE trial
Stephan R. Targan et al.
GASTROENTEROLOGY (2007)
Epithelia: lymphocyte interactions in the gut
Stephanie Dahan et al.
IMMUNOLOGICAL REVIEWS (2007)
Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab
Bruce E. Sands et al.
INFLAMMATORY BOWEL DISEASES (2007)
Oxidative stress and pathogenesis of inflammatory bowel disease: An epiphenomenon or the cause?
Ali Rezaie et al.
DIGESTIVE DISEASES AND SCIENCES (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn's disease? A systematic meta-analysis of controlled clinical trials
Roja Rahimi et al.
BIOMEDICINE & PHARMACOTHERAPY (2007)
Onercept for moderate-to-severe Crohn's disease: A randomized, double-blind, placebo-controlled trial
Paul Rutgeerts et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
SB Hanauer et al.
GASTROENTEROLOGY (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Natalizumab induction and maintenance therapy for Crohn's disease
WJ Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease
S Schreiber et al.
GASTROENTEROLOGY (2005)
Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin
BG Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study
TA Winter et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis
SJH van Deventer et al.
GUT (2004)
Natalizumab for active Crohn's disease.
S Ghosh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease
BR Yacyshyn et al.
GUT (2002)
Infliximab in treatment of Crohn's disease: the Milan experience
S Ardizzone et al.
DIGESTIVE AND LIVER DISEASE (2002)
Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
WJ Sandborn et al.
GASTROENTEROLOGY (2001)
A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn's disease
FH Gordon et al.
GASTROENTEROLOGY (2001)
The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study
WA Faubion et al.
GASTROENTEROLOGY (2001)
Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease
S Schreiber et al.
GASTROENTEROLOGY (2001)
分享论文
